Coherus BioSciences Advances Key Oncology Assets from Surface Acquisition

The strategic acquisition of Surface Oncology by Coherus BioSciences, finalized in September 2023, has ceased the former's independent trading status. However, its scientific legacy now forms a core component of Coherus's expansion plans. Recent progress on antibody candidates Casdozokitug and Tagmokitug illustrates how the biopharmaceutical company intends to leverage this acquired pipeline for growth.

Coherus is channeling resources into two primary clinical assets obtained through the deal. Casdozokitug (SRF388), an IL-27-targeting antibody, is currently undergoing Phase 2 trials for applications in lung cancer and liver cancer. The other significant candidate, Tagmokitug (CHS-114), is a CCR8-directed antibody. Notably, the development focus for Tagmokitug has evolved, with combination therapies taking precedence.

This strategic pivot is informed by data. Assessments from February 2026 indicate that Tagmokitug has demonstrated only limited efficacy as a standalone, or monotherapy, treatment. Consequently, researchers now believe its full therapeutic potential will likely be unlocked when it is used alongside other cancer drugs. The central aim of this approach is to achieve a more potent modulation of the immune response within the tumor microenvironment, thereby significantly boosting effectiveness compared to single-agent use.

Should investors sell immediately? Or is it worth buying Surface Oncology?

Anticipated 2026 Data and Portfolio Impact

For investors, the current year is set to deliver critical clinical readouts. A major point of interest involves the pairing of Tagmokitug with another therapeutic agent, Loqtorzi. Initial results from a Phase 1 study evaluating this combination are anticipated before the end of 2026.

This clinical investigation is focused on treating adenocarcinomas of the stomach and the gastroesophageal junction. The forthcoming data will be instrumental. They are expected to clarify the therapeutic value of targeting the CCR8 pathway and provide concrete evidence of how much the acquired Surface Oncology assets can contribute to the long-term strength of Coherus BioSciences's overall oncology portfolio. Future updates on these programs will predominantly center on Tagmokitug's performance within these combined treatment regimens.